
Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.
This paper explores a Quality by Design (QbD) approach to applying Artificial Intelligence (AI) in pharma manufacturing, and demonstrates how to leverage third party platforms to qualify AI algorithms for pharmaceutical product and medical device productivity chains.






